Refine
Document Type
- Article (4)
- Bachelor Thesis (1)
- Report (1)
Has Fulltext
- yes (6)
Is part of the Bibliography
- no (6)
Keywords
- Al-Jazeera (1)
- Clinical Trials and Observations (1)
- Friedensverhandlungen (1)
- Geheimnisverrat (1)
- Immunology (1)
- Lymphoid Neoplasia (1)
- Nahost-Konflikt (1)
- Oncology (1)
- Palestine Papers (1)
- Puja (1)
- Ritual (1)
- Ritual Studies (1)
- Ritualdynamik (1)
- Ritualtransfer (1)
- Wikileaks (1)
- anti-neural autoantibodies (1)
- antibodies (1)
- at-risk mental state (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- b-cell lymphomas (1)
- bendamustine (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- clinical high at-risk mental state (1)
- healthy control (1)
- hematopoietic stem cell transplantation (1)
- leukapheresis (1)
- lymphoma (1)
- rituximab (1)
- schizophrenia (1)
- ultra-high risk for psychosis (1)
“Kurz mal Weltmacht” überschrieb die ZEIT letzte Woche ihren Artikel, der den Untergang von WikiLeaks und das Ende Julian Assanges nachzeichnete. Auch Hoffnungsträger scheitern, hieß es, und der finanzielle Bankrott stelle ein eher wenig rühmliches Ende dar. Und trotzdem, so das Resümee, die Idee hinter seinem Projekt bleibe am Leben. In welche Richtung sie sich für den Nahost-Konflikt verwirklicht, wagt allerdings kaum jemand zu bewerten...
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
(2022)
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell–mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell–mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
The pathophysiological role of neural autoantibodies in acute psychotic disorders is receiving increased attention. However, there is still an ongoing debate, whether predominantly psychotic manifestations of autoimmune encephalitides exist that may remain undetected and, thus, untreated. Furthermore, it is discussed if such conditions can be diagnosed based on serum antibody results or if a reliable diagnosis requires additional cerebrospinal fluids (CSF) results. In this study, we screened pairs of serum and CSF samples from antipsychotic-naïve individuals with first-episode schizophrenic psychosis (FEP, n = 103), clinical high risk for psychosis (CHR, n = 47), and healthy volunteers (HV, n = 40) for eight different antibodies against various antigens that have been shown to be associated with autoimmune encephalitides: N-methyl-D-aspartate receptor (NMDAR, NR1 subunits only), glutamic acid decarboxylase (GAD65), leucine-rich glioma inactivated protein 1 (LGI1), contactin-associated protein-like 2 protein (CASPR2), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subunit 1, AMPAR subunit 2, γ-aminobutyric acid-B receptors (GABABR), and glycine receptors. All patients were within the norm with regards to a careful neurological examination, a magnetic resonance imaging (MRI) of the brain, an electroencephalogram (EEG), and routine blood pathology. All CSF samples were autoantibody-negative. In three serum samples of individuals with FEP, we detected low-titer CASPR2 immunoglobulin (Ig) G antibodies (≤1:160, n = 2) and non-IgG antibodies against NMDAR (n = 1) (overall serum-autoantibody prevalence in FEP: 2.91%). However, the IgG titers were below the laboratory cut-off defined for positivity, and non-IgG antibodies are of no clinical relevance. This suggests that there were no cases of autoimmune encephalitis in our cohort. Our results highlight the importance and the high specificity of CSF analysis to reliably detect autoantibodies. They confirm the hypothesis that pure psychotic manifestations of antibody-associated autoimmune encephalitides without any additional neuropsychiatric findings are very rare. However, special attention must be paid to those presenting with atypical mental illnesses with additional neurological symptoms, evidence of clinically-significant cognitive involvement, profound sleep-wake perturbations, seizures, electroencephalographic, or magnetic resonance imaging pathologies to be able to identify cases with autoimmune-mediated psychiatric syndromes.
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect on symptom reduction and on general well being of patients suffering from psychosis. However, questions regarding the specific efficacy of CBT, the treatment safety, the cost-effectiveness, and the moderators and mediators of treatment effects are still a major issue. The major objective of this trial is to investigate whether CBT is specifically efficacious in reducing positive symptoms when compared with non-specific supportive therapy (ST) which does not implement CBT-techniques but provides comparable therapeutic attention. Methods: The POSITIVE study is a multicenter, prospective, single-blind, parallel group, randomised clinical trial, comparing CBT and ST with respect to the efficacy in reducing positive symptoms in psychotic disorders. CBT as well as ST consist of 20 sessions altogether, 165 participants receiving CBT and 165 participants receiving ST. Major methodological aspects of the study are systematic recruitment, explicit inclusion criteria, reliability checks of assessments with control for rater shift, analysis by intention to treat, data management using remote data entry, measures of quality assurance (e.g. on-site monitoring with source data verification, regular query process), advanced statistical analysis, manualized treatment, checks of adherence and competence of therapists. Research relating the psychotherapy process with outcome, neurobiological research addressing basic questions of delusion formation using fMRI and neuropsychological assessment and treatment research investigating adaptations of CBT for adolescents is combined in this network. Problems of transfer into routine clinical care will be identified and addressed by a project focusing on cost efficiency. Discussion: This clinical trial is part of efforts to intensify psychotherapy research in the field of psychosis in Germany, to contribute to the international discussion on psychotherapy in psychotic disorders, and to help implement psychotherapy in routine care. Furthermore, the study will allow drawing conclusions about the mediators of treatment effects of CBT of psychotic disorders. Trial Registration Current Controlled Trials ISRCTN29242879
Rituale geben Menschen Stabilität und Kraft im täglichen Leben. Durch eine Migration können sich Modifikationen in der Performanz und Materialität der Rituale ergeben. Die Bachelorarbeit befasst sich mit diesen Veränderungen am Beispiel der Materialität des Hindu Rituals Puja. Das Ziel der Arbeit ist die Betrachtung, inwiefern aufgrund einer Migration Aneignungsprozesse in der Materialität stattfinden und diese ein Beispiel für Ritualdynamik sein können. Basierend auf den Ergebnissen eines in 2021/22 durch die Verfasserin durchgeführten Projekts im Rhein-Main Gebiet wird beschrieben, welche Gaben von den Gläubigen benutzt werden, welche Beschaffungsprozesse durchlaufen werden und welche Bedeutung eventuelle Veränderungen für die Gläubigen haben. Hierzu werden die Hypothesen erstellt und bestätigt, dass ein Aneignungsprozess und somit ein ritualdynamischer Prozess stattfindet und die Puja, aufgrund ihrer Flexibilität, ein geeignetes Ritual zur zukünftigen Untersuchung von Ritualdynamik darstellt.
Zunächst legt die Autorin den ethnologischen Ritualbegriff unter anderem über die Ritualtypen von Ronald L. Grimes dar und erörtert die Theorien der ritual studies. Des Weiteren wird der Forschungsstand des Themenbereichs der Ritualdynamik anhand der Ergebnisse und Theorien des Sonderforschungsbereichs 619 (SFB 619) in Heidelberg (2002-2013) erläutert. Darauffolgend werden nach einer kurzen Vorstellung des Hindu-Glaubens und den Grundlagen der Puja die Erkenntnisse aus dem Forschungsprojekt dargelegt. Anhand der Ergebnisse aus Interviews, teilnehmenden und passiven Beobachtungen und einer Umfrage mithilfe eines Fragebogens wird die Veränderung bei der Materialität des Rituals am Beispiel der angebotenen Speisen (naivedya) und dem Wasser des heiligen Flusses Ganges (gangagel) beschrieben. Die Flexibilität des Rituals wird anhand von Bespielen durch Informanten veranschaulicht. Abschließend werden die Hypothesen bearbeitet und ein Ausblick in die Zukunft des Themas aus Sicht der Verfasserin gegeben.